Termination of Taenia solium Transmission

Summary and Comment |
June 15, 2016

Termination of Taenia solium Transmission

  1. Larry M. Baddour, MD

A three-phase control program was successful in a highly endemic region in northern Peru.

  1. Larry M. Baddour, MD

Following relatively recent advances in the diagnosis, treatment, and prevention of infection due to Taenia solium, a well-funded multinational group sought to affect the transmission of this infection in a highly endemic area in northern Peru. The study's interventions involved both humans and pigs to maximize the likelihood of success in achieving transmission elimination. Outcomes were measured in pigs only, because of potential latency of clinical manifestations in human infection and the overall low prevalence of taeniasis. The researchers used serology and necropsy to identify pigs with live, nondegenerated cysts that could be responsible for infection transmission.

The study was conducted in three phases. Phase 1 included pig replacement, human education, and screening and treatment in both humans and pigs, and had limited success. In phase 2, mass treatment and mass screening of pigs and humans were conducted, with and without pig vaccination; 6 villages had infected pigs 1 year later, of which 5 villages had not had vaccinations done. In phase 3, mass treatment in both humans and pigs and vaccination in pigs was done. Following phase 3 activities, no infected pig was identified in 105 of the 107 villages included in the investigation. The authors plan to expand elimination efforts in Peru, collect data on costs of these interventions, and define less-expensive interventions that are effective and relatively easy to incorporate into prevention strategies.


The results of this investigation provide further evidence that major accomplishments in public health can be achieved if funding is available to multinational collaborative groups with unique expertise.

Editor Disclosures at Time of Publication

  • Disclosures for Larry M. Baddour, MD at time of publication Royalties UpToDate, Inc. (Authorship duties)


Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.